Table 2.
Clinical features of intrahepatic cholangiocarcinoma patients with hepatitis B virus infection and without hepatitis virus infection
| Variable | Without hepatitis | With hepatitis B | p value |
|---|---|---|---|
| Total patients | 108 (82.4) | 19 (14.5) | |
| Mean age, yr | 67.5 (60.5–76.0) | 57.0 (52.0–64.0) | 0.002 |
| Sex | |||
| Men | 61 | 10 | NS |
| Women | 47 | 9 | |
| Bilirubin, mg/dL | 0.7 (0.5–1.1) | 0.8 (0.6–1.1) | NS |
| Albumin, mg/dL | 3.6 (3.3–4.0) | 3.9 (3.4–4.3) | 0.044 |
| CA 19-9, mg/dL | 81.1 (16.5–877.6) | 149.3 (19.5–756.3) | NS |
| AFP, mg/dL | 3.0 (2.5–5.0) | 7.0 (3.0–190.8) | 0.016 |
| CTP score | 5 (5–6) | 5 (5–5) | NS |
| TNM stage | NS | ||
| I | 15 (13.9) | 4 (21.1) | |
| II | 10 (9.3) | 2 (10.5) | |
| III | 3 (2.8) | 0 | |
| IV a | 37 (34.3) | 6 (31.6) | |
| IV b | 43 (39.8) | 7 (36.8) | |
| Mean survival, day | 213 (105–435) | 302 (96–686) | NS |
| HBV viral load, IU/mL | 231 (20–409) | ||
| Antiviral treatment | |||
| Yes | 8 (42.1) | ||
| No | 11 (57.9) |
Values are presented as number (%) or median (interquartile range).
NS, no statistically significant; CA 19-9, carbohydrate antigen 19-9; AFP, α-fetoprotein; CTP, Child-Turcotte-Pugh; TNM, tumor-node-metastasis; HBV, hepatitis B virus.